For the year ending 2025-12-31, GALT has $19,532K in assets. $145,727K in debts. $17,720K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 17,720 | |||
| Prepaid expenses and other current assets | 1,716 | |||
| Total current assets | 19,436 | |||
| Other | 96 | |||
| Total assets | 19,532 | |||
| Accounts payable | 3,245 | |||
| Accrued expenses | 4,722 | |||
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (note 5) | 0 | |||
| Current portion of derivative liabilities (note 6) | 0 | |||
| Accrued dividends payable | 63 | |||
| Total current liabilities | 8,030 | |||
| Convertible notes payable and accrued interest, net of debt discounts related party (note 5) | 32,702 | |||
| Derivative liabilities (note 6) | 3,962 | |||
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (note 10) | 101,033 | |||
| Total liabilities | 145,727 | |||
| Series c 6 super dividend redeemable convertible preferred stock 1,000 shares authorized, 176 issued and outstanding at december 31, 2025 and 2024, redemption value 7,966,000, liquidation value 1,760,000 at december 31, 2025 | 1,723 | |||
| Series a 12 convertible preferred stock 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at december 31, 2025 and 2024, respectively, liquidation value 1,210,000 at december 31, 2025 | 490 | |||
| Common stock, 0.001 par value 150,000,000 shares authorized at december 31, 2025 and 2024, 65,201,995 and 63,157,235 issued and outstanding at december 31, 2025 and 2024, respectively | 65 | |||
| Additional paid-in capital | 304,073 | |||
| Accumulated deficit | -432,546 | |||
| Total stockholders deficit | -127,918 | |||
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | 19,532 | |||
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)